923 related articles for article (PubMed ID: 26405770)
21. Current Management of Polypoidal Choroidal Vasculopathy.
Tan CS; Lim TH; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Sep; 46(8):786-91. PubMed ID: 26431293
[No Abstract] [Full Text] [Related]
22. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
23. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
24. Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan.
Kokame GT; Omizo JN; Kokame KA; Yamane ML
Ophthalmol Retina; 2021 Oct; 5(10):954-961. PubMed ID: 34022443
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy.
De Salvo G; Vaz-Pereira S; Keane PA; Tufail A; Liew G
Am J Ophthalmol; 2014 Dec; 158(6):1228-1238.e1. PubMed ID: 25152500
[TBL] [Abstract][Full Text] [Related]
26. EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.
Tan CS; Ngo WK; Lim LW; Tan NW; Lim TH;
Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):1923-1930. PubMed ID: 27142805
[TBL] [Abstract][Full Text] [Related]
27. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
Ngo WK; Chee WK; Tan CS; Lim TH
BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
[TBL] [Abstract][Full Text] [Related]
28. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
29. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings.
Khan S; Engelbert M; Imamura Y; Freund KB
Retina; 2012 Jun; 32(6):1057-68. PubMed ID: 22127224
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive vascular imaging of polypoidal choroidal vasculopathy by Doppler optical coherence tomography.
Miura M; Muramatsu D; Hong YJ; Yasuno Y; Iwasaki T; Goto H
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3179-86. PubMed ID: 26024101
[TBL] [Abstract][Full Text] [Related]
31. Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Anti-Vascular Endothelial Growth Factor Treatment Response in Caucasians.
Kokame GT; Liu K; Kokame KA; Kaneko KN; Omizo JN
Ophthalmologica; 2020; 243(3):178-186. PubMed ID: 31707394
[TBL] [Abstract][Full Text] [Related]
32. Non-ICGA treatment criteria for Suboptimal Anti-VEGF Response for Polypoidal Choroidal Vasculopathy: APOIS PCV Workgroup Report 2.
Chong Teo KY; Sadda SR; Gemmy Cheung CM; Chakravarthy U; Staurenghi G; Invernizzi A; Ogura Y; Ruamviboonsuk P; Chen SJ; Gupta V; Tan C; Chhablani J; Corvi F; Kim JE; Gomi F; Koh AH; Kokame G; Mitchell P; Wong TY; Lee WK; Lai TYY
Ophthalmol Retina; 2021 Oct; 5(10):945-953. PubMed ID: 33866022
[TBL] [Abstract][Full Text] [Related]
33. [Tomographic features of polypoidal choroidal vasculopathy lesions by spectral domain optical coherence tomography].
Li HY; Dai RP; Dong FT; Chen YX
Zhonghua Yan Ke Za Zhi; 2011 Aug; 47(8):715-20. PubMed ID: 22169611
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of Polypoidal Choroidal Vasculopathy Evaluated by Optical Coherence Tomography Angiography.
Tomiyasu T; Nozaki M; Yoshida M; Ogura Y
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT324-30. PubMed ID: 27409489
[TBL] [Abstract][Full Text] [Related]
35. Polypoidal choroidal vasculopathy, diagnosis and management.
Coppens G; Spielberg L; Leys A
Bull Soc Belge Ophtalmol; 2011; (317):39-44. PubMed ID: 21560855
[TBL] [Abstract][Full Text] [Related]
36. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Cho HJ; Kim K; Lim SH; Kang DH; Kim JW
Br J Ophthalmol; 2020 Oct; 104(10):1443-1447. PubMed ID: 31896542
[TBL] [Abstract][Full Text] [Related]
37. Optical coherence tomographic enhanced depth imaging of polypoidal choroidal vasculopathy.
Yang LH; Jonas JB; Wei WB
Retina; 2013 Sep; 33(8):1584-9. PubMed ID: 23584691
[TBL] [Abstract][Full Text] [Related]
38. COMBINING EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WITH STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY AND BLOOD FLOW ANALYSIS FOR DETECTING CHOROIDAL NEOVASCULAR COMPLEXES IN PIGMENT EPITHELIAL DETACHMENTS.
Kang H; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Retina; 2019 Aug; 39(8):1551-1561. PubMed ID: 29863533
[TBL] [Abstract][Full Text] [Related]
39. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.
Mukai R; Itagaki K; Honjyo J; Tanaka K; Norikawa K; Sekiryu T
Jpn J Ophthalmol; 2024 May; 68(3):211-215. PubMed ID: 38609716
[TBL] [Abstract][Full Text] [Related]
40. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
